Advaxis (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXSGet Rating) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.

Advaxis Stock Performance

ADXS stock opened at $3.61 on Tuesday. Advaxis has a 52-week low of $1.02 and a 52-week high of $51.60.

About Advaxis

(Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Further Reading

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.